Shots:
- The US FDA has granted Nereus for the prevention of vomiting induced by motion, backed by 3 trials, incl. 2 P-III real-world boat studies (Motion Syros & Motion Serifos) & 1 supporting study in pts with documented motion sickness
- In Motion Syros (n=365) & Motion Serifos (n=316), vomiting incidence was 18.3–19.5% & 10.4–18.3% vs 44.3% & 37.7% with PBO, respectively, achieving more than 50–70% risk reduction in Motion Serifos
- Additionally, Vanda is advancing tradipitant for gastroparesis & for preventing nausea & vomiting associated with GLP-1 receptor agonists
Ref: PRnewswire | Image: Vanda | Press Release
Related News: Vanda Pharmaceuticals Seeks FDA Approval for Imsidolimab to Treat Generalized Pustular Psoriasis (GPP)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
